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Background: Metastatic melanoma is a devastating disease with limited therapeutic options. MicroRNAs (miRNAs)
are small non coding RNA molecules with important roles in post-transcriptional gene expression regulation, whose
aberrant expression has been implicated in cancer.
Results: We show that the expression of miRNAs from a large cluster on human chromosome 14q32 is significantly
down-regulated in melanoma cell lines, benign nevi and melanoma samples relative to normal melanocytes. This
miRNA cluster resides within a parentally imprinted chromosomal region known to be important in development
and differentiation. In some melanoma cell lines, a chromosomal deletion or loss-of-heterozygosity was observed in
the cis-acting regulatory region of this cluster. In several cell lines we were able to re-express two maternally-
induced genes and several miRNAs from the cluster with a combination of de-methylating agents and histone de-
acetylase inhibitors, suggesting that epigenetic modifications take part in their silencing. Stable over-expression of
mir-376a and mir-376c, two miRNAs from this cluster that could be re-expressed following epigenetic manipulation,
led to modest growth retardation and to a significant decrease in migration in-vitro. Bioinformatic analysis
predicted that both miRNAs could potentially target the 3'UTR of IGF1R. Indeed, stable expression of mir-376a and
mir-376c in melanoma cells led to a decrease in IGF1R mRNA and protein, and a luciferase reporter assay indicated
that the 3'UTR of IGF1R is a target of both mir-376a and mir-376c.
Conclusions: Our work is the first to show that the large miRNA cluster on chromosome 14q32 is silenced in melanoma.
Our results suggest that down-regulation of mir-376a and mir-376c may contribute to IGF1R over-expression and to
aberrant negative regulation of this signaling pathway in melanoma, thus promoting tumorigenesis and metastasis.
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Malignant melanoma is a devastating disease with a con-
stantly increasing incidence worldwide and limited treat-
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reproduction in any medium, provided the orcoding RNA molecules that are generated within cells and
play a role in post-transcriptional gene regulation [2]. It is
becoming clear that aberrant expression of miRNAs has a
role in cancerous transformation and progression [3]. Sev-
eral miRNA-profiling studies in melanoma were published
until now [4–6], but the picture emerging from these works
is far from being clear.
A large miRNA cluster was recently shown to be down-
regulated in ovarian cancer, and eight miRNAs in this clus-
ter were identified as potential tumor suppressor genes [7].
Lately, this cluster was also implicated in gastro-intestinalLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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mir-127 from this cluster was shown to have tumor sup-
pressor function in a bladder cancer model [10]. This
miRNA cluster lies within a parentally imprinted chromo-
somal area designated Dlk1-Gtl2 in mouse or Dlk-Dio3 in
human [11]. This area is of great developmental import-
ance, exemplified by severe phenotypes associated with
altered dosages of the genes within it in mice and humans
[12]. The regulation of imprinting in this chromosomal
locus is thought to be mediated, at least to some extent, by
an intergenic differentially methylated region (IG-DMR)
that is located centromeric to the imprinted region [13].
Indeed, this region was shown to be differentially methy-
lated during embryonic development in humans [14].
Another regulatory region, located more telomeric, is
designated 'MEG3-DMR'. Human studies performed on
infants with uniparental dysomy of each of these DMRs
imply that the IG-DMR and the MEG3-DMR function as
imprinting control centers in the placenta and the body, re-
spectively, with a hierarchical interaction for the methyla-
tion pattern in the body governed by the IG-DMR [15]. In
mouse, deletion of IG-DMR from the maternally (but not
the paternally) inherited chromosome causes bi-directional
loss of imprinting of all genes in the cluster [11]. A meticu-
lous characterization of all transcripts in this mouse locus
demonstrated that the miRNAs within this cluster were ex-
clusively expressed from the maternal chromosome. The
other maternally expressed transcripts in this region (desig-
nated Meg3 and Meg8) were found to have exclusive pat-
terns of expression, being detected only in brain, testis and
skin [16]. Very recently, the expression of miRNAs from
this region was found to be essential for maintaining full
pluripotency of induced pluripotent stem cells [17].
Along the years, there have been few descriptions of
chromosomal abnormalities in melanoma samples.
15 years ago, the translocation t(1;14)(q21;q32) was
found in several of 20 melanoma samples taken from
patients [18], and more than a decade later this chromo-
somal region was again found to be aberrant in some
melanoma cell lines [19]. Recently, Zhang et al. deter-
mined DNA copy number abnormalities in 283 miRNA
genes in three different cancer types (namely ovary,
breast and melanoma) using comparative genomic
hybridization, and showed loss of hetrozygocity (LOH)
of the 14q32 miRNA cluster in 20% of the melanoma
cell lines examined [20]. Nonetheless, this cluster has
not been specifically implicated in melanoma so far.
We show here that this large miRNA cluster is silenced
in melanoma cell lines, benign nevi and melanoma sam-
ples, and present data suggesting that both genetic and
epigenetic mechanisms may take part in this silencing.
We provide data showing that re-expression of mir-376a
and mir-376c, two miRNAs from this cluster, lead to at-
tenuation of melanoma proliferation and migration. Thesetwo miRNAs target IGF1R, a tyrosine kinase receptor
implicated in melanoma tumorigenesis and metastasis.
Results
To compare the miRNA expression pattern between normal
and malignant melanocytes, two samples of miRNAs pro-
duced from normal human epidermal melanocytes (NHEM)
and miRNAs from five melanoma cell lines were hybridized
to a commercial miRNAs array, using commercial placental
miRNAs as positive control (Additional file 1). An unsuper-
vised cluster anlysis of the logarithm of the normalized
values using the k-means clustering algorithm showed that
the two NHEM samples exhibit a very similar pattern of
miRNAs expression, and that whereas the majority of miR-
NAs are not significantly altered between normal and malig-
nant melanocytes (cluster #3, Figure 1A), there are two
distinct groups of miRNAs that are either up-regulated or
down-regulated in melanoma vs. melanocytes (cluster #2
and #1, respectively, Figure 1A). The expression pattern of
several miRNAs from the array was validated by quantitative
RT-PCR, and all were found to exhibit similar expression
patterns as in the array (Figure 1B and results not shown).
Statistical analysis was undertaken to find miRNAs
who exhibit the exact same pattern of expression (i.e.
significant up-regulation or down-regulation) in all five
melanoma cell lines compared to normal cells by using a
student t-test with a p value< 0.0032 (corrected for mul-
tiple comparisons with a false discovery rate of 0.05).
Using this very stringent criterion, only 58 miRNAs were
found to be significantly altered between normal mela-
nocytes and all five malignant melanoma cell lines, out
of which 57 were significantly down-regulated in melan-
oma. Interestingly, of these 57 miRNAs, 27 were mapped
to a large bipartite miRNA aggregate on chromosome
14. This cluster resides within a parentally imprinted re-
gion on chromosome 14q32 known to be imperative in
development and differentiation (Figure 1C) [12,15]. We
therefore decided to focus our present work on miRNAs
from this large aggregate. Table 1 depicts the expression
pattern of all miRNAs from this cluster.
We next compared the expression pattern of miRNAs
from benign melanocytic nevi and melanoma samples
taken from parrafin-embedded tissues to miRNAs from
normal melanocytes (Additional file 2). In general, the
expression patterns of miRNAs from benign nevi and
malignant melanoma were very similar. Interestingly,
chromosome 14q32 miRNAs were significantly over-
represented in the cluster of miRNAs whose expression
was significantly down-regulated in all melanoma and
nevi. Whereas chromosome 14q32 miRNAs accounted
for 7.6% of all miRNAs represented on the array (65 out
of 851), they accounted for 23.5% of all the downregu-
lated miRNAs (19 out of 81, p< 0.002 using chi-square,
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Figure 1 (See legend on next page.)
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Figure 1 The expression pattern of miRNAs in normal melanocytes and melanoma cell lines, and the organization of the 14q32
imprinted region. (A) Heat map representing a cluster analysis of the logarithm of the normalized values of ~800 miRNAs embedded on a
commercial array in normal melanocytes (two samples) and five different melanoma cell lines. (B) The expression levels of five different miRNAs
using qRT-PCR (black) or data obtained from the array (grey). Data is represented as mean±SEM, * signifies p< 0.05 (C) The organization of the
Dlk-Gtl2 region on human chromosome 14q32. The positions of miRNAs within this region are marked in rectangular boxes. The maternal allele is
colored pink; the paternal allele is colored light-blue. The blue boxes signify paternally-expressed transcripts, and the red boxed signify
maternally-expressed transcripts. The direction of transcription is marked with an arrow. The color of the hairpin at the IG-DMR illustrates the
methylation status at the region; black – methylated, white hypo-methylated. (D) The expression levels of four miRNAs from the chromosome-
14q32-cluster in normal melanocytes (NHEM), benign nevi (NEV) and melanoma samples (MEL) using qRT-PCR. Data is normalized relative to
NHEM and is represented as mean±SEM, * signifies p< 0.05.
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qRT-PCR on miRNA produced from two different sam-
ples of NHEM, fifteen samples of benign nevi and seven
samples of melanoma. All miRNAs examined were sig-
nificantly down-regulated in nevi and melanoma relative
to NHEM (Figure 1D and results not shown).
Previous work in mice showed that silencing of the
maternally-expressed genes (coding for mRNAs and
miRNAs) could result from deletion of the regulatory
IG-DMR region [11], whereas in an in-vitro human
model system, epigenetic modifications led to re-
expression of a miRNA from this cluster [10]. We thus
hypothesized that the apparent miRNA silencing from
chromosome 14 could be the result of a chromosomal
deletion of the regulatory region, epigenetic modifica-

























The expression levels of 65 miRNAs from the large miRNA cluster on human chroma control element for all imprinted genes on the mater-
nal chromosome [11], and since the miRNAs are
thought to be transcribed only from the maternal
chromosome [16], we first designed a DNA copy num-
ber assay using quantitative real time PCR with two dif-
ferent probes taken from the IG-DMR region. As
expected, there were two copies of each of the two
probes in the DNA taken from a healthy human subject,
in the DNA of normal melanocytes and in the DNA of
most of the melanoma cell lines. However, there were
two melanoma cell lines that exhibited only one copy of
the IG-DMR DNA, and no copies of either of the two
probes were detected in another cell line (Table 2).
These results suggest that LOH or complete absence of
the IG-DMR locus could explain the miRNA silencing
in some, but not all, of the melanoma cell lines.in melanoma
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Table 2 IG-DMR copy number in melanoma cell lines
Cell type Calculated Copy number
Normal DNA 2
Normal melanocytes (NHEM) 2







The calculated IG-DMR copy number as assessed using qPCR in normal human
DNA, DNA from normal melanocytes and seven melanoma cell lines.
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this locus. The maternally expressed genes Meg3 and
Meg8, known to be selectively expressed only in brain,
skin and testis [16], were detected in normal but not in
malignant melanocytes. The paternally expressed genes
Rtl1 and Dio3 were detected in all cell lines (Figure 2A).
To assess whether epigenetic modifications take part in
silencing from this cluster, we searched for conditions
and combinations of epigenetic modifiers (de-methylat-
ing agents and HDAC inhibitors) that might bring about
re-expression of the maternal genes from this cluster.
Both maternal transcripts could be re-expressed after
several days of treatment with a combination of the de-
methylating agent 5 azacytidine (5-AZA) and the HDAC in-
hibitor valproic acid (VPA) but not with any of these agents
alone (resuls not shown). The re-expression of the maternal
expressed genes was observed in most of the cell lines exam-
ined, and was even more pronounced when using the
HDAC inhibitor phenyl butyric acid (PBA; Figure 2B).
Re-expression of mir-127 was assessed using the same
treatment conditions. Mir-127 could be induced between
8 to 30–fold using this treatment combination in all mel-
anoma cell lines examined (Figure 2C). To verify that the
treatment indeed led to epigenetic modifications in the
vicinity of the regulatory region of the 14q32-cluster, chro-
matin immunoprecipitation (ChIP) using an anti-
acetylated Histone 3 antibody was performed, showing
that the addition of epigenetic modifiers increased the ex-
tent of histone acetylation in two different loci within the
IG-DMR region and in another regulatory region located
approximately 700 bp upstream of the mir-127 locus [10]
(Figure 2D), suggesting that re-expression of these miR-
NAs is a result of a true epigenetic alteration in the cells.
We utilized the micro-array platform to see which
other chromosome-14-miRNAs could be induced using
the combination of HDAC inhibitors and de-
methylating agents (Additional file 3). Interestingly, out
of all 65 chromosome-14-miRNAs assessed in four mel-
anoma cell lines, only five miRNAs were shown to beinduced in any of the cell lines: mir-127-3p, mir-137,
mir-376a (also designated mir-376a-3p), mir-376c and
mir-485-3p. These five miRNAs, expressed in normal
melanocytes, could not be further up regulated in these
cells in response to epigenetic modifiers (Table 3). Four
of these five miRNAs (mir-127-3p, mir-136, mir-376a
and mir-376c) were found to be down-regulated but not
entirely silenced in nevi and melanoma (Additional file
2). Results obtained with the more sensitive method of
qRT-PCR verified that mir-376a, mir-376c and mir-136
can be significantly induced following treatment with
epigenetic modifiers in most of the melanoma cell lines
(Figure 2E and results not shown).
Mir-127 was previously shown to target BCL-6 in a
bladder cancer model [10], so we first generated melan-
oma cell lines that ectopically express mir-127 in a stable
manner. In our experimental system, mir-127 over-
expression did not lead to a significant decrease in BCL-6
levels in melanoma cell lines, nor did it lead to a signifi-
cant change in melanoma cell line proliferation or migra-
tion in vitro (results not shown). We therefore decided to
focus on other miRNAs whose expression was shown to
be down-regulated but not entirely absent in melanoma
and as a first step generated melanoma cell lines that ecto-
pically express either mir-376a or mir-376c (Figure 3A).
Cells over-expressing either mir-376a or mir-376c exhib-
ited attenuated growth relative to pTER-transfected control
cells (Figure 3B). This effect was modest yet statistically
significant, leading to approximately 25-30% decrease in
cell growth after 96 hours. This growth pattern was also
observed using a micro-electronic biosensor system (desig-
nated 'real-time-cell-analyser', RTCA [21]) that allows real-
time monitoring of cell growth in-vitro (Figure 3C). Cellu-
lar migration was monitored using an in-vitro transwell
system. Mir-376a and mir-376c transfected cells showed
significantly attenuated migration through a transwell
membrane 24 hours after seeding relative to pTER-
transfected control cells (Figure 3D). Migration was also
monitored using the real-time-cell analyzer, this time asses-
sing cell density following passage through a membrane as
described in [22]. Whereas pTER-transfected control mel-
anoma cells exhibited a time-dependent migration through
the membrane, the mir-376a and mir-376c transfected cells
showed almost no migration through the membrane
within a 24 h period (Figure 3E).
Bioinformatic analysis using several web-based tools
showed that miRNA-376a and miRNA-376c have puta-
tive binding sites at the 3'UTR of IGF1R (Figure 4A), a
tyrosine kinase receptor long known to be implicated in
melanoma tumorigenesis and progression [23]. The pu-
tative binding site of mir-376c is classified as ‘7mer-
8mer binding’, and that of mir-376a is classified as ‘8mer
binding’. Both putative binding sites are located within
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Figure 2 (See legend on next page.)
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Figure 2 Re-expression of maternally expressed transcripts from chromosome 14q32 following treatment with epigenetic modifiers
and its effect on histone acetylation. (A) The expression levels of the maternal (Meg3, Meg8) and paternal (Rtl1, Dio3) genes in normal
melanocytes (NHEM) and melanoma cell lines. (B) The expression levels of Meg3 and Meg8 following treatment with 10 μM 5-AZA+1.5 mM VPA (v)
or 10 μM 5-AZA+3 mM PBA (p) in five different cell lines. (C) The expression level of mir-127 in melanoma cells treated with epigenetic modifiers
(10 μM 5-Aza and 3 mM PBA), as assessed by qRT-PCR and normalized relative to untreated cells. (D) ChIP assay of 14PA melanoma cells untreated or
treated with 10 μM 5-Aza and 3 mM PBA. The normalized levels of chromosomal DNA at three different loci following immunoprecipitation with anti-
acetylated histone 3 in control cells and in cells treated with epigenetic modifiers are shown. Data is represented as mean±SEM, * signifies p< 0.05. (E)
The expression level of mir-376a and mir-376c in cells untreated or treated with 10 μM 5-Aza and 3 mM PBA.
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IGF1R 3'UTR through additional nucleotide pairing be-
yond the "seed" sequence [24, 25] (Figure4A).
As expected, both mRNA and protein levels of IGF1R
were higher in melanoma cell lines than in normal melano-
cytes (Figure 4B). Stable expression of mir-376a or mir-
376c led to a decrease in IGF1R levels both at the mRNA
and at the protein levels (Figure 4C). In order to determine
whether IGF1R is a direct target of miR-376a/c, we used a
commercial plasmid containing the first ~2800 nucleotides
of the IGF1R 3'UTR cloned downstream to the luciferase
reporter gene. This vector was then introduced into melan-
oma cells over-expressing mir-376a, mir-376c or a control
vector (designated pTER). Introduction of the IGF1R-3
'UTR-luciferase vector into pTER-transfected control cells
led to a ~40% decrease in the level of luciferase expression
relative to the same cells following introduction with a con-
trol luciferase vector. This probably reflects the negative
regulatory action of endogenous miRNAs within the melan-
oma cells on this 3'UTR. Introduction of the IGF1R-3'UTR-
luciferase vector into mir-376a-transfected or mir-376c-
transfected cells led to a significant ~83% and ~65% de-
crease in the level of luciferase expression relative to the
same cells following introduction with a control luciferase
vector, respectively, indicating that the stable expression of
both miRNAs leads to further significant down-regulation
on the 3'UTR of IGF1R (Figure 4D), thus establishing
IGF1R as a target of both mir-376a and mir-376c.Table 3 Re-expression of chromosome 14q32 miRNAs





Mel33B1 14PA Mel526 Mel624
5aza + PBA - + - + - + - + - +
Mir-127 70.6 61.4 UD UD 7.1 37.3 UD 9.5 UD UD
Mir-136 52 44.4 UD UD 7.9 30.8 UD UD UD UD
Mir-376a 100.1 75.4 UD UD UD 12.4 UD UD UD UD
Mir-376c 122.1 77.6 UD UD UD 10.4 UD UD UD UD
Mir-485-3p 12.7 18.4 UD 23.9 37.7 38.6 31.1 19.2 UD 16
The expression levels of five chromosome-14q32 miRNAs in normal
melanocytes and four melanoma cell lines as assessed by miRNA micro-array
following treatment with epigenetic modifiers (10 μM 5-Aza and 3 mM PBA);
UD-undetected. The miRNAs with significant differences between treatment
and control are boldedTo assess whether the down-regulation of IGF1R by mir-
376a and mir-376c could account for the observed bio-
logical phenotype in these cells, IGF1R was pharmacologic-
ally inhibited using the commercially-available IGF1R
inhibitor AG-1024 [26]. IGF1R inhibition by AG-1024
pheno-copied the decrease in migration seen following
over-expression of either mir-376a or mir-376c using the
same experimental system, in a dose-dependent manner
(Figure 4E). The administration of AG-1024 to melanoma
cells over-expressing either mir-376a or mir-376c did not
lead to a further decrease in their migration (results not
shown), suggesting that the IGF1R axis could not be fur-
ther modulated to decrease migration. AG-1024 did not
lead to decreased cellular proliferation in either the control
cells or the cells over-expressing mir-376a or mir-376c,
suggesting that the modest effect of these miRNAs on cel-
lular growth is mediated through different mechanisms.
Discussion
We show here that miRNAs from a large cluster on
chromosome 14q32 are significantly down-regulated or
absent in melanoma cell lines, benign nevi and melanoma
samples relative to normal melanocytes. This may suggest
that their expression is lost along the transformation
process of normal melanocytes into malignant cells. This
resembles the well-known observation that the mutated
form of B-RAF, which characterizes 40-60% of melanoma
patients [27], can already be detected in benign pigmented
nevi as well [28]. It is well-known that an acquired muta-
tion in B-RAF is not sufficient for tumorigenesis [29]. We
hypothesize that in a similar manner, the loss of expres-
sion of this miRNA cluster occurs already in the benign
phase, but contributes to tumorigenesis and metastasis
only upon the acquisition of additional genetic and cellu-
lar abnormalities.
The miRNA cluster on chromosome 14q32 has been
shown to be down-regulated in ovarian cancer ([7], gastro-
intestinal stromal tumors (GIST) [8] and gliomas [9], and
aberrations in chromosome 14 have been implicated in
many types of cancer (reviewed in [9]). In fact, this region
was already dubbed 'the largest miRNA tumor suppressor
cluster [9]. A recent review summarized the growing body
of literature connecting this region to cancer in many sites
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Figure 3 The effect of stable expression of mir-376a and mir-376c on the proliferation and migration of melanoma cells. (A) qRT-PCR
analysis of mel33B1 melanoma cells after stable transfection with an empty pTER vector or vectors containing either mir-376a (left) or mir-376c
(right). The relative expression levels are numerically depicted. (B) The growth of mel33B1 melanoma cell lines transfected with pTER, mir-376a
and mir-376c was assessed using the crystal-violet method for 96 h. * signifies p< 0.05, *^ signifies p< 0.08 (C) The growth of mel33B1
melanoma cell lines transfected with pTER, mir-376a and mir-376c was assessed using the Xcellience TM real-time system. (D) The migration of
these three cell lines was assessed using the in-vitro transwell method. Representative micrographs of the transwell membrane are seen. This
experiment was repeated three times. (E) Cellular migration was assessed using the Xcellience TM real-time system within a 24 h period.
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cently been published [4–6], all in agreement that only sev-
eral miRNAs are differentially expressed between normal
melanocytes and melanoma cell lines or samples. Neither
work pointed to the almost complete disappearance of
miRNA expression from this cluster. This is most likely due
to methodological differences between the different works.Some of the chromosome-14q32-miRNAs were expressed
in very low amounts in normal melanocytes, thus perhaps
‘evading’ detection with miRNA arrays of lower sensitivity
than the one used in our current work, whereas at least ten
miRNAs from the cluster were expressed in higher levels
than the median expression level in the array. It is important




Human      GUUCCUAGGACUUCUUCAUGGGUCUUACAGUUCUAUGUUAGACCAUGAAACAUUUGCAUACACAUCGU
Chimpanzee GUUCCUAGGACUUCUUCAUGGGUCUUACAGUUCUAUGUUAGACCAUGAAACAUUUGCAUACACAUCGU
Mouse      GUUACUAGGACUUCUUCAUGGGUCUCUCAGUUCUAUGUUAGACCGUGAAACAUUUGCAUACACAUCGU
Rat        GUUACUAGGACUUCUUCAUGGGUCUCUCAGUUCUAUGUUAGACCCUGAAACAUUUGCAUACGCAUCGU
Rabbit     GUUACUGGGACUUUCUCAUGGGUCUUACAGUUCUAUGUUAGACCGUGAAGCAUUUGCAUACACAUCAU
Cat        GUUACUAGGACUUCUUCAUGGGUCUUACAGUUCUAUGUUAGACCAUGAAACAUUUGCAUACACAUCGU
Lizard     AUUAUUGAGACUUC-AAAAGGGUCUGGCAGUUCUAUGUUAGACCACGGAUCAUUUGCAUACACAUUGU
Chicken  UUAUUAUUAAGACUUCUCGAAGGGUCUUGCAGUUCUAUGUUAGACCAUGGAUCAUUUGCAUACACAUUGU
Mir-376c seed
1162-1168 of IGF1R-3'UTR 5'CAUGGGUCUUACAGUUCUAUGUU...
|||||||
hsa-miR-376c               3'UGCACCUUAAAGGAGAUACAA 
.....1290........1300......1310........1320.........1330.......
Human           UUGUUCUUGAUCUUUGUGGAUUUAAUCUAU--GAAAACCUUCAGGUCCA-CCC-UCUCCCCUU 
Chimpanzee      UUGUUCUUGAUCUUUGUGGAUUUAAUCUAU—-GAAAACCUUCAGGUCCA-CCC-UCUCCCCUU
Mouse           UUGUUCUUUAUCUUUGUGGAUUUAAUCUAU--GAAA-CUUUCAGGUCUACCCC-UUCUUCCUU
Rat             UUGUUCUUUAUCUUUGUGGAUUUAAUCUAU--GAAA-CUUUCAGGUCUA-CCC-UUCUUCCUU
Rabbit          UCGUUCCUUCUCUUUGUGGAUUUAAUCUAU--GAAA-UCUUCAGGUCUCUG-CUUUCCUCCCU
Cat             UUGUCCUUUAUCUUUGUGGAUUUAAUCUAU--GAAAACCUUCAGGUCUA-CCCUCCUUCCCUC
Lizard          UUGUUCUUUAUCUUUGUGGAUUUAAUCUAUAAGAAAUACUUCAGGUCUA-CCCCCCCUUCCUU 
Mir-376a seed
1307-1314 of IGF1R-3'UTR  5'UUGUGGAUUUAA-UCUAUGAA
||||||||   |||||||







































































Figure 4 (See legend on next page.)
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Figure 4 Establishment of IGF1R as a target of mir-376a/c. (A) The 3'UTR of the IGF1R gene showing potential binding sites for mir-376a/c
(marked in grey). The sequence conservation from human to lizard in the vicinity of mir-376c and 376a seed sequences and the putative
interaction of the miRNAs and the mRNA are shown (taken from TargetScan at http://www.targetscan.org/). (B) IGF1R mRNA and protein levels in
NHEM and several melanoma cell lines using qRT-PCR and Western blot, respectively. (C) IGF1R mRNA and protein levels in pTER-transfected and
mir-376a/c-transfected mel33B1 melanoma cells using qRT-PCR and Western blot, respectively. (D) Melanoma cell lines stably transfected with
pTER, mir-376a or mir-376c were transiently transfected with a control-luciferase vector or with a vector containing luciferase attached to an
element of the 3'UTR of the IGF1R gene containing the putative binding sited for mir-376a/c (designated IGF1R 3'A). The ratio of expression of
luciferase/renilla was normalized relative to control-transfected cells for each of the cell lines. * signifies p< 0.05 using two-way ANOVA. (E) The
migration of control pTER-transfected melanoma cells was assessed in the absence and in the presence of varying doses of AG-1024 using the in-
vitro transwell method. Representative micrographs of the transwell membrane are seen. This experiment was repeated three times.
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http://www.molecular-cancer.com/content/11/1/4414q32-miRNAs and maternal transcripts were consistently
seen in all normal melanocyte samples examined by us from
several different batches, using both the micro-array tech-
nique and qRT-PCR. Indeed, Stark et al. characterized the
‘melanoma miRNAome’ by performing deep sequencing of
cell lines derived from normal melanocytes, melanoblasts,
melanoma and a large congenital nevus, and also demon-
strated that Chromosome-14q32-miRNAs are expressed in
normal melanocytes but not in any melanoma cell lines [31],
in complete agreement with our current work. Moreover,
Philippidou et al. also observed that both mir-127-3p and
mir-376c are down-regulated in a metastatic cell line relative
to their expression in the primary tumor from the same pa-
tient [5], again in agreement with our current observations.
Genetic analysis in mice elegantly showed that a mater-
nal deletion of the IG-DMR region could lead to a shut-
down of the expression of genes from the maternal
chromosome, thus rendering the expression pattern from
this chromosome to be 'paternal-like' [11]. Our copy num-
ber assay indicates that LOH of the IG-DMR or complete
absence of two copies of this region occurs in less than
half of the cell lines examined. Our results are in line with
published results, showing that 20% of the melanoma cell
lines exhibit copy number losses in miRNA genes in
chromosome 14q32 [20]. Nonetheless, LOH of the IG-
DMR region is clearly not the sole mechanism underlying
this miRNA cluster shut-down. Interestingly, an LOH
spanning approximately 1.1 Mb in the same region on
chromosome 14q32 was found to characterize many cases
of neuroblastoma [32], a neoplasm derived from neural
crest cells, the precursor cells from which mature melano-
cytes develop as well.
Recent studies suggested that the expression of Dlk1-
Dio3 transcribed miRNAs is essential for maintaining full
pluripotency of induced pluripotent stem cells (iPSCs),
and that this expression is in fact the most significant dis-
criminator between fully pluripotent and partially pluripo-
tent inducible cells [17,33]. These works, albeit descriptive
in nature, again point to the cardinal role of this large
miRNA locus on the fine interplay between differentiation,
pluripotency and transformation.We observed that only a combination of de-methylating
agents and HDAC inhibitors (designated 'epigenetic modi-
fiers' in short) could lead to re-expression of two mater-
nally expressed genes and only very few miRNAs from this
cluster. We could not find a correlation between the num-
ber of copies of the IG-DMR region and the potential or
the extent of re-expression following treatment, suggesting
that epigenetically ‘switching on’ a silenced allele is feasible
whether there are two alleles in the cell or only one.
The observed increase in the levels of acetylated-
histone-3 DNA in three different loci within the regula-
tory regions following treatment with epigenetic modi-
fiers suggests that epigenetic alterations takes part in
silencing of this cluster. The observation that only a few
miRNAs from the cluster could be re-expressed after
treatment with epigenetic modifiers was somewhat sur-
prising. Four of these miRNAs (namely mir-127-3p, mir-
136, mir-376a and mir-376c) were shown to be down-
regulated but not completely silenced in nevi and mela-
nomas. These results, taken together, suggest that the
regulation of the expression of miRNAs from this cluster
is complex and multi-leveled. Whereas previous results
suggest that the IG-DMR is an important regulatory
'switch' in this region [34], our work suggest that it is by
no means the only one. One can postulate that specific
miRNAs within this large cluster have their own individ-
ual 'switches', and indeed such a switch has been sug-
gested for mir-127 [10], also shown to be up regulated
in our work in response to epigenetic modifiers.
Ectopic expression of mir-376a and mir-376c had a
modest yet significant effect on cell growth, but a pro-
found effect on cellular migration in-vitro. Indeed, it has
already been suggested that melanoma proliferation and
migration are controlled through different regulatory cir-
cuits [35]. The Insulin growth factor 1 receptor was re-
cently shown to be constitutively activated in melanoma
cells in an autocrine fashion [36]. Insulin-like growth
factor 1 (IGF-1) was shown by others to significantly in-
crease melanoma cell migration in-vitro through activa-
tion of the IGF1R. IGF1-stimulated migration required
PI3K activation but was independent of MAPK/ERK
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were higher in melanoma cell lines than in normal mela-
nocytes, and the ectopic expression of mir-376a and
mir-376c led to down-regulation of the receptor. Luci-
ferase reporter assays indicate that, as bioinformatically
predicted, mir-376a and mir-376c directly target IGF1R.
Pharmacological inhibition of IGF1R pheno-copied the
decrease in migration seen following mir-376a and mir-
376c over-expression, suggesting that down-modulation
of the IGF1R signaling pathway may be responsible for
the observed anti-migratory effect of these miRNAs in
melanoma cell lines.
Other miRNAs have been shown to down-regulate IGF1R.
For example, mir-145, a known tumor-suppressor-miRNA,
was shown to inhibit the IGF1R axis by targeting both IRS-1
and IGF1R [38]. Recently, mir-493 (curiously also located on
chromosome 14q32) was shown to be capable of inhibiting
liver metastasis in a colon cancer model by targeting IGF1R
[39]. Nonetheless, the inhibition of IGF1R by mir-376a and
mir-376 has not been described before.
Conclusions
We show here that a large miRNA cluster on chromo-
some 14q32 is silenced in malignant melanoma. This
cluster has been implicated in many cancers, as well as
in differentiation and in determination of pluripotency,
but not in melanoma so far. This silencing may involve
genetic or epigenetic mechanisms, and can partly be
reverted in-vitro using epigenetic modifiers such as de-
methylating agents and HDAC inhibitors. Re-expression
of two miRNAs from this cluster, namely mir-376a and
376-c, attenuate melanoma proliferation and migration.
Both these miRNAs target IGF1R.
IGF1R has already been implicated in melanoma almost
20 years ago [40], and data concerning its exact role in the
pathogenesis of this disease is rapidly accumulating
(reviewed in [23]). Eight years ago the IGF1/IGF1R pair was
shown to lead to melanoma migration [37], and in fact
IGF1R was recently identified as a potential target in melan-
oma using a phosphoproteomic screen [41]. Last, in-vitro
work showed that resistance to B-RAF inhibition could be
overcome by simultaneously co-targeting MEK and IGF1R/
PI3K, and that indeed IGF1R levels are increased in human
tumor sample following the acquisition of resistance to B-
RAF inhibition, consistent with a role for IGF1R/PI3K-
dependent survival in the development of such resistance
[42]. More specifically, the possibility of targeting the IGF1R
by siRNAs in B-RAF-mutated melanoma cells was also
already suggested several years ago [43].
The work presented here demonstrates that mir-376a
and mir-376c negatively regulate IGF1R, and suggests
that aberrations in this regulatory mechanism, in the
form of down-regulation of mir-376a/c, take part in mel-
anoma progression and metastasis. In lieu of growinginterest in this pathway in relation to B-RAF inhibition,
our work may, in the future, contribute to further under-
standing of the phenomenon of resistance to B-RAF
inhibition.Methods
Cells cultures and reagents
Melanoma cell lines were generated directly from meta-
static melanoma lesions of patients at the Surgical
branch of the NIH (mel526, mel624, mel938, mel33A1,
mel33B1;[44,45]) or at the ‘Ella institute for melanoma
research’ at the Sheba Medical center (eng-003, 14PA,
15AY [46]). The cell lines were grown in DMEM
medium supplemented with 10% fetal bovine serum
(FBS), 1% Penicillin–Streptomycin antibiotics, 1% L-glu-
tamine and 2.5% HEPES solution (Biological Industries,
Kibbutz Beit Haemek, Israel). Normal human epidermal
melanocytes (NHEM) were purchased (three different
batches throughout the period of research) from Promo-
cell (C-12400; Promocell, Germany) and grown in mel-
anocyte growth medium (C-24010; Promocell) according
to manufacturer's instructions. NHEM were maintained
in culture for up to 5 cycles.
AG-1024 (a commercially-available IGF1R inhibitor)
was purchased from Calbiochem- EMD Biosciences (La
Jolla, CA, USA).Cloning
Both mir-376a and mir-376c pre-miRNAs were cloned into
the pTER plasmid [47,48]. It is to note that there are two
miRNA genes, mir-376a-1 and mir-376a-2, coding identi-
cal mature miRNAs, that are indistinguishable. Briefly,
both sense and anti-sense oligos of the pre-miRNA were
synthetically synthesized (Sigma, Israel). Sequences were









GATC (the complementary sequence to BglII digested)
was added to the 5' end of the sense oligo, and TCGA
(the complementary sequence to HindIII digested) was
added to the anti-sense oligo. Sense and anti sense oligos
were Annealed and ligated into the pTER vector
digested with BglII and HindIII.
Table 4 Primer sequences used for assessment of mRNA
levels by qRT-PCR
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HmiT009523-MT01) and control plasmid (no 3'UTR;
CmiT000001-MT01) were purchased from GeneCopoeia,
Inc. (Rockville, MD).
Generation of stable melanoma cell lines
Cells were transfected with purified DNA plasmids with
the Lipofectamine™ 2000 Transfection Reagent (Invitro-
gen, Carlsbad, CA), according to the manufacturer
protocol. 24 hours after transfection, Zeocin antibiotic
(300μg/ml) was added to the cells for selection. Follow-
ing selection, the stable ectopic expression of mir-376a/c
was repeatedly assessed using qRT-PCR.
Tumor samples
Formalin-fixed-parrafin-embedded (FFPE) samples of benign
nevi or primary cutanous melanoma were obtained from the
pathology institute at the Sheba Medical Center. The initial
diagnosis of melanoma and the histological type was verified
by a pathologist on the hematoxylin-eosin–stained slides,
performed on the first and/or last sections of the sample.
The tumor or nevus was macro-dissected from the slide in
the cases in which the sample contained normal tissues as
well, based on demarcations delineated by the pathologist.
The study was approved by the ethics committee of Sheba
Medical Center and conducted in adherence to the Declar-
ation of Helsinki protocols.
RNA extraction
Total RNA was extracted from cell lines using Ambion
mirVana™ miRNA Isolation Kit (Ambion, Austin, TX).
Total RNA from 10 sections of 5 μm FFPE tissues was
extracted using the Qiagen miRNeasy FFPE kit (Qiagen,
Germantown, MD). Quantity and quality were evaluated
using a Nanodrop ND-2000 (Thermo Scientific, Wal-
tham, MA) with inclusion criteria of A260/A280 ≥1.8.
For positive control, a commercial sample of placental
miRNAs was used (Ambion, Austin, TX).
miRNA micro-array experimentation and analyses
miRNA expression profiling was performed using Agilent’
Human miRNA Micro-array system V2 and later V3
(Agilent Technologies, Santa Clara, CA) with probe sets
for approximately 850 human miRNAs (taken from the
‘miRBase’ database) according to the manufacturer’s proto-
col . In brief, 100 ng of total RNA were fluorescently-
labeled with Cyanine 3-pCp, and hybridized onto the arrays
for 18–20 h at 55 °C. Slides were scanned in an Agilent
micro-array scanner G2565BA and the images obtained
were processed with Feature Extraction Software 9.5.3.1
(Agilent, Santa Clara, CA). Cluster analysis was done on
the normalized, log transformed values with the k-means
algorithm using the MATLAB software (MathWorks,
Natick, MA).Quantitative real time PCR
MiRNA
Quantification of miRNAs by TaqMan MicroRNA assays
(Applied Biosystems, Carlsbad, CA) was carried out using
10 ng of RNA. Target miRNA expression was normalized
between samples based on the expression levels of Rnu19
or Rnu48. The ΔΔCT method was used to calculate the ex-
pression values.
mRNA
IGF1R mRNA levels was assessed with the TaqManW
Gene Expression Assay (ID Hs99999020_m1 IGF1R).
Gene expression was normalized between different sam-
ples based on the values of Rplpo expression.
Copy number assay
Total cellular DNA was extracted using genomic DNA ex-
traction kit (iNtRON biotechnology, Seongnam, Korea).
Quantification of DNA by TaqMan Copy Number assays
was carried out using 10 ng of DNA with the primers
Hs03889256_cn, Hs03874180_cn, Hs03877160_cn (Applied
Biosystems, Carlsbad, CA). Genomic Rnase P region served
as a reference assay. Analyzes were done using the 'Copy-
CallerTM software' (Applied Biosystems, Carlsbad, CA).
Determination of mRNA levels by RT-PCR
Reverse transcription-polymerase chain reaction (RT-PCR)
was performed using the Verso thermo-scientific kit
(Thermo-Scientific, Waltham, MA). PCR primers are listed
(Table 4).
Treatment with epigenetic modifiers
Cells were seeded at 50% confluence 8 hr prior to treatment
with 5-Aza-2'-deoxycytidine (5-Aza 10 μM; Sigma-Aldrich,
Rehovot, Israel) and valproic acid (VPA 1.5 mM; Sigma-
Aldrich, Rehovot, Israel) or phenylbutyric acid (PBA 3 mM;
Sigma-Aldrich, Rehovot, Israel). The drugs were continuously
administered by replacing the medium every 24 h for 5 days.
Chromatin-immunoprecipitation (ChIP) assay
\14PA melanoma were cells treated with 5-Aza and
PBA and subjected to a ChIP assay using a modified
protocol as decribed in [49]. In short, cells were
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resuspended in 1% SDS-containing buffer and then
sonicated. Extracts were immunoprecipitated with anti-
acetylated histone H3 antibody (Millipore, Billerica,
MA) overnight at 4°C. Quantitative analysis was per-
formed by real-time PCR with TaqMan primers as fol-
lows: Hs03889256_cn and Hs03874180_cn, both located
within the 8 kb-long IG-DMR region (approximately
15 kb upstream of Gtl2 and 70 kb downstream of the
Dlk1 promotor); and Hs03877160_cn, located approxi-
mately 700 bp upstream of mir-127 (Applied Biosys-
tems, Carlsbad, CA).Luciferase assay
Luciferase assay was performed 48 h post transfection
with a control vector or a vector containing part of the
3'UTR of the IGF1R using the Dual Luminescence
Assay Kit (GeneCopoeia, Inc., Rockville, MD) as
described by the manufacturer.Determination of protein expression level by western
blotting (WB)
WB was performed using monoclonal primary specific
antibodies (IGF1Rβ c20 CS-713, Santa Cruz Biotechnol-
ogy, USA, and Beta Actin AC-15, Abcam, UK) as per-
viously described [50].Cell growth and migration in-vitro
Crystal violet
Melanoma cells (5 × 103) were seeded in a 96-well plates
and viable cell counts were monitored from seeding
time to 96 h. The cells were fixated with ethanol 70%
and stained with crystal violet 0.1%. The color was
extracted using 1% triton x-100 and absorption was
read at 550 nm. Each experiment was performed in
quadruplicate, and repeated at least three times.Transwell migration
Melanoma cells (2× 105) were seeded in the upper wells
of a Transwell migration system on ThinCertsTM inserts
with 8-μm membranes (Greiner-bio-one, Frickenhausen,
Germany) in DMEM supplemented with 0.1% FBS. The
lower well contained the same medium with 10% FBS.
After 24 hours of incubation, the upper well content,
which contained non-migrating cells, was vigorously
removed using cotton swabs. The cells that migrated
through the membranes were fixated with 70% cold
Ethanol, stained with crystal violet 0.1% and photo-
graphed using the light microscope. Each experiment
was performed in triplicate, and repeated three times.Real-time-cell-analyser (RTCAW)
Melanoma cells were seeded in the xCELLigenceTM DP
system (Roche Diagnostics GmbH, Mannhein, Germany)
and incubated for 1–5 days. For monitoring growth, data
were collected every 20 min automatically by the
analyzer as described in [21]. For verification, a cellular
growth curve was also obtained using the crystal violet
technique described above. For monitoring migration,
cells were seeded in the upper chamber in the normal
culture medium of the respective cell line with 0.1%
FBS. This upper chamber was then placed on the lower
part of the CIM-device containing growth medium sup-
plemented with 10% FBS as an attractant. Migration of
the cells was followed for 24 h by tracking changes of
the impedance signal in a CIM-plate measured on the
opposing side of the membrane as described in [22].
Each experiment was performed in duplicates and
repeated twice.
Statistical analysis
Statistical significance was determined using the Stu-
dent’s t-test or using two-way ANOVA. For a single
comparison, a p-value< 0.05 was considered significant.
For multiple comparisons, a p-value< 0.0032 was used,
taking into account multiple comparisons using the
method of false detection rate (FDR).
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